Update of evidence in chemotherapy for breast cancer

International Journal of Clinical Oncology

Volumn 13, Issue 1, 2008, Pages 3-7

  Yamashiro, Hiroyasu ^a   Toi, Masakazu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Individualization; Molecular; Profiling

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CLINICAL TRIAL; DRUG TARGETING; GENE EXPRESSION PROFILING; HUMAN; MULTIPLE CYCLE TREATMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG THERAPY, COMPUTER-ASSISTED; FEMALE; GENE EXPRESSION PROFILING; HUMANS; TAXOIDS;

EID: 40149099855     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-007-0719-1     Document Type: Review

References (29)

1. Goldhirsch A, Wood W, Gelber R, et al. (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
3. Berry DA, Cirrincione C, Henderson IC, et al. (2006) Estrogen receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1662
4. Pritchard KI, Shepherd LE, O'Malley FP, et al.; National Cancer Institute of Canada Clinical Trials Group (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111
5. Paik S, Bryant J, Tan-Chiu E, et al. (2000) HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991-1998
6. Dressler LG, Berry DA, Broadwater G, et al. (2005) Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23:4287-4297
7. Scandinavian Breast Group Trial 9401; Tanner M, Isola J, Wiklund T, et al. (2006) Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neuamplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24:2428-36. Epub 2006 May 8
8. Knoop AS, Knudsen H, Balslev E, et al. (2005) Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490
9. Bhargava R, Lal P, Chen B (2005) HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 123:889-895
10. Martin M, Pienkowski T, Mackey J, et al. (BCIRG 001) (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313
11. Roche H, Fumoleau P, Spielmann M, et al. (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671
12. Martin M, Rodriguez-Lescure A, Ruiz A, et al. (2005) Multicenter, randomized phase III study of adjuvant chemotherapy for nodepositive breast cancer comparing six cycles of FE90C versus four cycles of FE90C followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 trial. Breast Cancer Symposium: San Antonio 11 Dec 2005, abstract #39
13. Mamounas EP, Bryant J, Lembersky B, et al. (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005 23:3686-3696
14. Henderson IC, Berry DA, Demetri GD, et al. (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983
15. Sparano JA, Wang M, Martino S, et al. (2007) Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of Intergroup Trial E1199. J Clin Oncol (Meeting Abstracts) 25: abstract #516
16. Jones SE, Savin MA, Holmes FA, et al. (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387
17. Morris GJ, Naidu S, Topham AK, et al. (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110:876-884
18. Dent R, Trudeau M, Pritchard KI, et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434
19. Foulkes WD, Brunet JS, Stefansson IM, et al. (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid- microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830-835
20. Bhattacharyya A, Ear US, Koller BH, et al. (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899-23903
21. Tong AH, Evangelista M, Parsons AB, et al. (2001) Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 294:2364-2368
22. Huang F, Reeves K, Han X, et al. (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226-2238
23. Carey LA, Dees EC, Sawyer L, et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334
24. Rouzier R, Perou CM, Symmans WF, et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685
25. Paik S, Shak S, Tang G, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
26. Paik S, Tang G, Shak S, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 24:3726-3734
27. van't Veer LJ, Dai H, van de Vijver MJ, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536
28. van de Vijver MJ, He YD, van't Veer LJ, et al. (2002) A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
29. Wang Y, Klijn JG, Zhang Y, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679